New Delhi, Jun 8: A group of 12 rectal cancer patients showed no signs of a tumour after taking an antibody drug for six months, according to a surprise finding from an ongoing medical trial in the US that experts termed optimistic.

Besides their tumours disappearing completely, none of the participants reported any severe side-effects either, says the research paper published in the New England Journal of Medicine recently.

The patients underwent a series of medical exams -- physical, endoscopy, bioscopy, PET scans and MRI scans -- and none of the reports showed a tumour.

All 12 patients had a clinical complete response, with no evidence of tumour on magnetic resonance imaging, the authors of the study said.

Longer follow-up is needed to assess the duration of response, they added.

The researchers set out to find whether dostarlimab, an antibody drug, followed by standard chemoradiotherapy and standard surgery is an effective treatment for advanced deficient MisMatch Repair' (dMMR) solid tumours.

MisMatch repair (MMR) deficient cells usually have many DNA mutations that lead to cancer. MMR deficiency is most common in colorectal cancer, other types of gastrointestinal cancer, and endometrial cancer, the Journal said.

Participants of the trial conducted at the Memorial Sloan Kettering Cancer Center in New York with mismatch repair-deficient stage II or III rectal adenocarcinoma were given the drug every three weeks for six months.

Adenocarcinoma is a type of cancer that develops in the glands that line our organs.

According to the initial plan, the treatment was to be followed by standard chemotherapy and surgery, and patients who had a clinical complete response would proceed without both.

After at least six months of follow-up, all 12 patients showed a clinical complete response with no signs of the tumour.

These results are cause for great optimism yet these are early days for the trial as well as for the patients who wish to embark on this treatment. This approach cannot supplant current curative multimodality treatment approach, said Dr. Nikhil S Ghadyalpatil, senior consultant, medical oncologist and hemato-oncologist at Hyderabad's Yashoda Hospitals.

Clinical complete response as an end point used in this study is an imperfect surrogate for long term cure and hence should be interpreted cautiously. We need larger placebo controlled studies with longer follow up in this setting to confidently consider using this approach in routine practice, Ghadyalpatil told PTI.

The treatment, the oncologist said, surely provides an early glimpse of a revolutionary approach in rectal cancer patients and authors of this study should be congratulated for this effort.

There have been no similar trials in India so far, he added.

Another similar international study with the drug pembrolizumab showed only 70 per cent patients had long term response at three years unlike 100 per cent response in the current study, he added.

Ghadyalpatil said pembrolizumab is available in India but dostarlimab used in the current study is not.

The cost of dostarlimab is not known in India but is expected to be a couple of lakhs per dose, he added.

Commenting on the trial, Dr. Hannah K. Sanoff of the North Carolina Cancer Hospital, said the results are optimistic but the treatment procedure used in the study cannot replace the current curative treatment approach.

Patients who have a clinical complete response after chemotherapy and radiation therapy have a better prognosis than those who do not have a clinical complete response, yet cancer regrowth occurs in 20 to 30 per cent of such patients when the cancer is managed nonoperatively, she wrote in an editorial on the trial.

Whether the results of this small study will be generalisable to a broader population of patients with rectal cancer is also not known, Sanoff said in the editorial printed in the New England Journal of Medicine.

She added that in order to provide further information on patients who might benefit from immunotherapy, subsequent trials should aim for heterogeneity in age, coexisting conditions, and tumour bulk .

The medical trial was supported by the Simon and Eve Colin Foundation, GlaxoSmithKline, Stand Up to Cancer, Swim Across America, and the National Cancer Institute of the National Institutes of Health.

Let the Truth be known. If you read VB and like VB, please be a VB Supporter and Help us deliver the Truth to one and all.

Meerut (UP) (PTI): Bharatiya Janata Yuva Morcha (BJYM) president Tejasvi Surya claimed on Tuesday that the BJP will get more seats in next year's Lok Sabha polls compared to the 2019 general election.

He also said the "double-engine" government led by the Bharatiya Janata Party (BJP) has changed the face of Uttar Pradesh.

Addressing a BJYM convention in Meerut, Surya said, "The BJP will get more seats in the 2024 polls than in 2019 and (Prime Minister Narendra) Modiji will score a hat-trick for a third innings."

The member of Parliament from Bangalore South also alleged that before 2014, when the Modi government came to power, there was a misrule in the country, adding that nine years of the Modi government have proved to be more effective than the 70 previous years. People's welfare is the topmost priority of this government, he said.

Surya said the "double-engine" government has changed the face of Uttar Pradesh, adding that thanks to Prime Minister Modi and Chief Minister Yogi Adityanath, the law-and-order scenario of the state has also improved.

"Double engine" is a term often used by BJP leaders to refer to the saffron party being in power at the Centre as well as in a state.

Surya said under Modi's leadership, India has got respect at the global stage, which is only increasing.

The prime minister is trying to take the country to new heights, he added.